Financials
Financial year 2025
Revenue
€ 241.2 million
▲ 13% vs 2024
Profit
Growing€ 7 million
▲ 33% vs 2024
Debts
High€ 52.8 million
▲ 9% vs 2024
GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline from Wavre, company number BE0403066474, closed financial year 2025 with a result of € 7 million after tax. For that financial year GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline recorded revenue of € 241.2 million and equity of € 4.8 million. Compared with financial year 2024, the result moved from € 5.3 million to € 7 million. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.
What happened at GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline?
What happened at GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 7 million (▲ 33% vs 2024). Source: NBB ↗
- Vincent Willemant stepped down as director. NBB
- Frédéric Martin stepped down as director. NBB
- Frédéric Martin became a director. NBB
- Vincent Willemant became a director. NBB
- New establishment in Wavre. KBO
- Start of the company according to the CBE. KBO
In short
From € 3 million profit in 2021 to € 7 million profit in 2025.
Paid € 10.1 million in corporate taxes since 2021.
Best year ever: 2025, with € 7 million profit.
Paid out € 35.9 million in dividends to the owners in total.
A new publication or filing at GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline? We notify you, reason included.
Follow GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKlineNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Setfirst Ltd (100%) and Edinburgh Pharmaceutical Industries Ltd (0%).
Directors
According to the 2025 annual accounts
Vincent Willemant
Director
since 2025 · until 2026
Frédéric Martin
Managing director
Also active at: ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE
since 2025 · until 2026
Shareholders
Setfirst Ltd
100%
Edinburgh Pharmaceutical Industries Ltd
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Avenue Fleming 20
1300 Wavre
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
Details
- Company number
- 0403.066.474
- VAT number
- BE 0403.066.474
- Registered office
- Avenue Fleming 20, 1300 Wavre
- Names & denominations
- GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline · GSK
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 January 1968
- Peppol
- Active · Active since 28 Oct 2025
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen